Income Statement Presentation 2023

Al submissions for existing products Projects in phase II and III New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology Other Roche RG3502 RG6264 Phesgo OBI RG7446 HER2+ BC Tecentriq¹ NSCLC periadj RG7446 Gavreto Tecentriq RG6396 RG7446 Tumor agnostic (US) SCCHN adj RG7446 RG7446 Tecentriq + cabozantinib RCC adv RG1594 Ocrevus SC RMS & PPMS Tecentriq + paclitaxel RG7446 TNBC adj RG7159 RG6413+ Ronapreve** RG7446 RG6412 SARS-CoV-2 hospitalized (EU) ✓ Tecentriq + Avastin HCC adj TNKase Tecentriq RG3625 RG7446 RG7159 stroke ctDNA+ high-risk MIBC Kadcyla + Tecentriq HER-2+ eBC high-risk Tecentriq High-risk NMIBC Tecentriq+ lurbinectedin 1l maintenance SCLC Gazyva Gazyva systemic lupus erythematosus membranous nephropathy Actemra Venclexta RG1569 RG7601 RG3648 COVID-19 pneumonia✓ r/r MM t(11:14) Xolair food allergy RG7601 Venclexta + azacitidine 1L MDS Ocrevus higher dose RG1594 RG7446 Tecentriq SC Tecentriq + capecitabine RG7446 all approved indications ✓ or carbo/gem RG6152 Xofluza direct transmission RG7159 Gazyva lupus nephritis RG6168 RMS & PPMS Enspryng MOG-AD TNBC Xofluza Polivy RG7596 RG7853 1L DLBCL (US)✓ Alecensa ALK+ NSCLC adj RG6152 influenza, pediatric (0-1 year) RG6168 Enspryng myasthenia gravis Enspryng RG6168 autoimmune encephalitis 2022 2023 2024 2025 and beyond Status as of February 2, 2023 ✓ Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU 1filing timeline based on data from interim analysis OBI-On-Body Delivery System **Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals 80

View entire presentation